Format

Send to

Choose Destination
Sci Rep. 2016 Mar 10;6:22850. doi: 10.1038/srep22850.

Human malignant mesothelioma is recapitulated in immunocompetent BALB/c mice injected with murine AB cells.

Author information

1
Chromatin Dynamics Unit, Division of Genetics and Cell Biology, San Raffaele Hospital, Milano, Italy.
2
HMGBiotech, Milano, Italy.
3
Experimental Imaging Center, San Raffaele Hospital, Milano, Italy.
4
Medical Physics Unit, San Raffaele Hospital, Milano, Italy.
5
Diagnostic Radiology Unit, San Raffaele Hospital, Milano, Italy.
6
IBFM-CNR, Segrate, Italy.
7
Health Sciences Dept., Milano Bicocca University, Milano, Italy.
8
Pathological Anatomy Laboratory, San Raffaele Hospital, Milano, Italy.
9
San Raffaele Vita-Salute University, Milano, Italy.
10
Molecular Oncology Unit, San Raffaele Hospital, Milano, Italy.
11
ISTOVET, Besana in Brianza, Monza e Brianza, Italy;
12
Fondazione Filarete, Milano, Italy.
13
Università degli Studi, Milano, Italy.
14
Division of Molecular Genetics, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
15
Mario Negri Institute, Milano, Italy.
16
Division of Pathology "Maggiore Della Carità" Hospital, Novara, Italy.

Abstract

Malignant Mesothelioma is a highly aggressive cancer, which is difficult to diagnose and treat. Here we describe the molecular, cellular and morphological characterization of a syngeneic system consisting of murine AB1, AB12 and AB22 mesothelioma cells injected in immunocompetent BALB/c mice, which allows the study of the interplay of tumor cells with the immune system. Murine mesothelioma cells, like human ones, respond to exogenous High Mobility Group Box 1 protein, a Damage-Associated Molecular Pattern that acts as a chemoattractant for leukocytes and as a proinflammatory mediator. The tumors derived from AB cells are morphologically and histologically similar to human MM tumors, and respond to treatments used for MM patients. Our system largely recapitulates human mesothelioma, and we advocate its use for the study of MM development and treatment.

PMID:
26961782
PMCID:
PMC4785401
DOI:
10.1038/srep22850
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center